CIBA-GEIGY CATAFLAM LAUNCH PLANNED FOR LATE JANUARY

CIBA-GEIGY CATAFLAM LAUNCH PLANNED FOR LATE JANUARY following the Nov. 24 approval of the nonsteroidal anti-inflammatory drug, diclofenac potassium. Cataflam contains the same active ingredient as Voltaten (diclofenac sodium), which Ciba has marketed in the U.S. since 1988. Cataflam will be launched "toward the end of January," Ciba said. On Jan. 17, company reps will begin detailing the product to doctors, including primary care physicians, OB/GYNs, orthopedic surgeons and emergency room physicians.